Speaker Profile
Ph.D., CEO & Co-Founder, Allelica Inc
Biography
Giordano Botta is the Co-Founder and CEO of Allelica Inc, where he drives the development and clinical implementation of multi-ancestry polygenic risk scores (PRS). Under his leadership, Allelica pioneered the first clinical multi-ancestry PRS test for Coronary Artery Disease (CAD), breast and prostate cancer, now used by leading healthcare systems. He focuses on cost-effectiveness analysis to ensure the long-term sustainability of PRS tests. Botta has overseen the creation of a software engine and the integration of genomic and clinical data from over one million individuals of diverse ancestries to develop and validate PRS. His primary interest is advancing the integration of PRS for CAD and common cancers into standard medical care, improving prevention and early intervention strategies.
Session Abstract – PMWC 2026 Silicon Valley
Track Chair:
Victor Velculescu, Johns Hopkins University
PMWC Award Ceremony
• Klaus Pantel, University Medical Center Hamburg-Eppendorf / ELBS
• Daniel De Carvalho, University of Toronto
Keynote: Early Detection of Cancer by Multimodal Liquid Biopsy Analysis
• Klaus Pantel, UKE / ELBS
From Mutation to Methylation: The Next Wave of Liquid Biopsy Biomarkers
• Chair: Victor Velculescu, Johns Hopkins University
• Daniel De Carvalho, University of Toronto
• Stephen Master, CHOP/U Penn
• Manel Esteller, Sant Pau Research Institute
• Gordon Sanghera, Oxford Nanopore Technologies
Advancing Minimal Residual Disease Detection Through cfDNA & cfRNA Profiling
• Chair: Luis Diaz, Memorial Sloan Kettering Cancer Center
• Anne-Renee Hartman, Adela
• Klaus Pantel, UKE / ELBS
• Rita Shaknovich, Agilent
• Ajay Gannerkote, Integrated DNA Tech
AI-Informed Biomarker Trials: Turning Early Signals into Actionable Designs
• Chair: Manish Kohli, University of Utah
• Luis Diaz, MSKCC
• Eric Klein, GRAIL
• Peter Bach, DELFI Diagnostics
• Anne Docimo, UnitedHealthcare
• Samuel Levy, ClearNote Health
Role of AI in Liquid Biopsies & Cancer Detection
• Chair: Amoolya Singh, DELFI Diagnostics
• Ron Andrews, Dxcover
• Pankaj Vats, NVIDIA
Fragmentomics for Early Detection: End Motifs and Library Prep
• Christopher Troll, Claret Bioscience
Integrating Genetic Risk with Early Detection: A Precision Prevention Framework for Cardiovascular Disease
• Giordano Botta, Allelica
Metagenomic Diagnostics & Global Pathogen Surveillance
• Charles Chiu, UCSF
AI-Driven Host–Pathogen Signatures from Plasma cfDNA: Bridging Infection Biology and Early Diagnostics
• Sivan Bercovici, Karius
Ultra-Sensitive Multimodal Liquid Biopsy for Early Cancer Detection: AI-Driven Signal Profiling
• John Sninsky, CellMax Life
AI-Enhanced Proteomic Signatures for Early Cancer Detection
• Diana Abdueva, Aqtual
• Sally Mackenzie, EpiMethyl Analytics
